MedTrace Logo

Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)

NCT07759362 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 554

Last updated 2026-08-12

No results posted yet for this study

Summary

The primary purpose of this study is to assess the efficacy, safety, and tolerability of KN3835 compared to placebo in the treatment of flexible/semi-flexible HMT.

Conditions

  • Flexible Hammertoe
  • Semi-flexible Hammertoe

Interventions

BIOLOGICAL

KN3835

Participants will receive KN3835.

OTHER

Placebo

Participants will receive placebo matching to KN3835.

Sponsors & Collaborators

  • Endo USA Inc., a Keenova Therapeutics Company

    lead INDUSTRY

Principal Investigators

  • Medical Director, MD · Endo USA Inc., a Keenova Therapeutics Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07759362 on ClinicalTrials.gov